At @ weeks , @ % of the combination therapy group achieved prolonged smoking abstinence and @ % achieved @-day point-prevalence smoking abstinence compared with @ % and @ % in varenicline monotherapy ( odds ratio -LSB- OR -RSB- , @ ; @ % CI , @-@ @ ; P = @ and OR , @ ; @ % CI , @-@ @ ; P = @ , respectively ) .